reddit.com· r/MultipleSclerosis · Reddit·· 19 hours agoPickScore66
Fenebrutinib gets priority review by the FDA
In brief
Roche's NDA for fenebrutinib was accepted by the FDA on 2026-09-30 and granted priority review. The drug is not yet approved, and no PDUFA date has been disclosed.
Why it matters
FENtrepid showed noninferiority to Ocrevus, a 12% reduction in disability progression risk, and HR 0.88, without statistically significant superiority.
Source: reddit.com · reddit.com